Esketamine vs SP-101

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

Esketamine · Spravato

Marketed by Johnson & Johnson

Approved in Major Depressive Disordersmall molecule
Partial signal

NCT02417064 · Phase 3 · completed

The study randomized 346 participants to double-blind 56 mg esketamine, 84 mg esketamine, or matching placebo, each with an oral antidepressant, and used the clinical MADRS depression score at Day 28 as its primary endpoint. The statistical analysis plan tested the 84 mg dose first and allowed a formal test of the 56 mg dose only if 84 mg was significant. The 84 mg dose did not separate from placebo (MMRM p=0.088), so the primary endpoint was missed. The 56 mg difference from placebo (LS mean -4.1 points) was outside the formal testing sequence and counts as nominal only.

Next expected readout: April 2027 · NCT06278779 (registry estimate)

Reported efficacy

Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase); Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis (Baseline up to Endpoint (Double-blind Induction Phase [Day 28])): Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) -21.4 Units on a scale (Standard Deviation 12.32) vs Intranasal Placebo Plus Oral AD -17 Units on a scale (Standard Deviation 13.88) (met)

Result source: NCT02418585

SP-101

Developed by Synphatec (Shanghai) Biopharmaceutical

Phase 1 in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEsketamineSP-101
MADRS, change (acute)-15.7 vs -12.4−3.3 vs placebo84 mg · wk 0.14 · n 113NCT03097133
64 other results
  • -16.4 vs -12.8 84 mg · wk 0.14 · n 111 · Phase 3 · primary NCT03039192
  • -18.8 vs -14.8 84 mg · wk 4 · n 98 · Phase 3 · primary NCT02417064
  • -17.4 vs -14.3 84 mg · wk 4 · n 113 · Phase 3 · primary NCT02417064
  • -19 vs -14.8 56 mg · wk 4 · n 111 · Phase 3 · primary NCT02417064
  • -18.3 vs -14.3 56 mg · wk 4 · n 115 · Phase 3 · primary NCT02417064
  • -21.4 vs -17 wk 4 · n 101 · Phase 3 · primary NCT02418585
  • -19.6 vs -16.3 wk 4 · n 112 · Phase 3 · primary NCT02418585
  • -10.1 vs -8.1 wk 4 · n 109 · Phase 3 · primary NCT03434041
  • -10 vs -6.3 wk 4 · n 63 · Phase 3 · primary NCT02422186
  • -9.3 vs -5.6 wk 4 · n 71 · Phase 3 · primary NCT02422186
  • -29.5 vs -25.8 84 mg · wk 3.57 · n 112 · Phase 3 · secondary NCT03039192
  • -24.5 vs -22 84 mg · wk 3.14 · n 114 · Phase 3 · secondary NCT03097133
  • -24 vs -21.6 84 mg · wk 3.14 · n 112 · Phase 3 · secondary NCT03039192
  • -23.1 vs -21.4 84 mg · wk 2.57 · n 114 · Phase 3 · secondary NCT03097133
  • -23.9 vs -21.4 84 mg · wk 2.57 · n 112 · Phase 3 · secondary NCT03039192
  • -23.4 vs -20 84 mg · wk 2.14 · n 114 · Phase 3 · secondary NCT03097133
  • -22.3 vs -20.4 84 mg · wk 2.14 · n 112 · Phase 3 · secondary NCT03039192
  • -21.3 vs -19.5 84 mg · wk 1.57 · n 114 · Phase 3 · secondary NCT03097133
  • -21.8 vs -19 84 mg · wk 1.57 · n 112 · Phase 3 · secondary NCT03039192
  • -20.1 vs -17.4 84 mg · wk 1.14 · n 114 · Phase 3 · secondary NCT03097133
  • -19.7 vs -17.4 84 mg · wk 1.14 · n 112 · Phase 3 · secondary NCT03039192
  • -17.7 vs -15.7 84 mg · wk 0.57 · n 114 · Phase 3 · secondary NCT03097133
  • -19.1 vs -14.5 84 mg · wk 0.57 · n 112 · Phase 3 · secondary NCT03039192
  • -16 vs -12.4 84 mg · wk 0.29 · n 114 · Phase 3 · secondary NCT03097133
  • -16.4 vs -12.9 84 mg · wk 0.29 · n 112 · Phase 3 · secondary NCT03039192
  • -13.5 vs -10.9 84 mg · wk 0.14 · n 112 · Phase 3 · secondary NCT03039192
  • -8 vs -4.4 wk 0.14 · n 123 · Phase 3 · secondary NCT03434041
  • -19.6 vs -17.8 wk 16 · n 327 · Phase 3 · secondary NCT04338321
  • -18.1 vs -13.7 wk 16 · n 327 · Phase 3 · secondary NCT04338321
  • -19 vs -17.1 wk 14 · n 327 · Phase 3 · secondary NCT04338321
  • -17.6 vs -13.2 wk 14 · n 327 · Phase 3 · secondary NCT04338321
  • -18.4 vs -16.7 wk 12 · n 327 · Phase 3 · secondary NCT04338321
  • -17.1 vs -13.1 wk 12 · n 327 · Phase 3 · secondary NCT04338321
  • -18.2 vs -16.2 wk 10 · n 327 · Phase 3 · secondary NCT04338321
  • -16.9 vs -12.8 wk 10 · n 327 · Phase 3 · secondary NCT04338321
  • -16.4 vs -14.3 wk 8 · n 327 · Phase 3 · secondary NCT04338321
  • -15.7 vs -12 wk 8 · n 327 · Phase 3 · secondary NCT04338321
  • -14.9 vs -12.2 wk 6 · n 327 · Phase 3 · secondary NCT04338321
  • -14.5 vs -10.7 wk 6 · n 327 · Phase 3 · secondary NCT04338321
  • -12.8 vs -9.8 wk 4 · n 327 · Phase 3 · secondary NCT04338321
  • -12.6 vs -8.9 wk 4 · n 327 · Phase 3 · secondary NCT04338321
  • -9 vs -6.1 wk 2 · n 327 · Phase 3 · secondary NCT04338321
  • -9 vs -5.8 wk 2 · n 327 · Phase 3 · secondary NCT04338321
  • -5.3 vs -3.7 wk 1 · n 327 · Phase 3 · secondary NCT04338321
  • -13.9 vs -7 84 mg · wk 4 · n 89 · Phase 4 · primary NCT04599855
  • -15.1 vs -15.3 84 mg · wk 4 · n 39 · Phase 2 · primary NCT02918318
  • -12.7 vs -7 56 mg · wk 4 · n 82 · Phase 4 · primary NCT04599855
  • -15.3 vs -4.9 84 mg · wk 1 · n 12 · Phase 2 · primary NCT01998958
  • -13.4 vs -9.1 84 mg · wk 0.0238 · n 35 · Phase 2 · primary NCT02133001
  • -14.5 vs -15.3 56 mg · wk 4 · n 34 · Phase 2 · primary NCT02918318
  • -15.2 vs -15.3 28 mg · wk 4 · n 39 · Phase 2 · primary NCT02918318
  • -11.4 vs -4.5 84 mg · wk 1 · n 5 · Phase 2 · primary NCT01998958
  • -12.4 vs -4.9 56 mg · wk 1 · n 11 · Phase 2 · primary NCT01998958
  • -10.3 vs -4.9 56 mg · wk 1 · n 9 · Phase 2 · primary NCT01998958
  • -8.9 vs -4.5 56 mg · wk 1 · n 9 · Phase 2 · primary NCT01998958
  • -9.8 vs -4.9 28 mg · wk 1 · n 11 · Phase 2 · primary NCT01998958
  • -7.6 vs -4.5 28 mg · wk 1 · n 8 · Phase 2 · primary NCT01998958
  • -4.8 vs -4.9 14 mg · wk 1 · n 11 · Phase 2 · primary NCT01998958
  • -1.2 vs -4.5 56 mg · wk 1 · n 3 · Phase 2 · primary NCT01998958
  • -6.6 vs -4.5 14 mg · wk 1 · n 5 · Phase 2 · primary NCT01998958
  • -26.4 vs -23 84 mg · wk 3.4286 · n 35 · Phase 2 · secondary NCT02133001
  • -19.3 vs -12.8 84 mg · wk 0.1429 · n 35 · Phase 2 · secondary NCT02133001
  • -13 vs -9.7 84 mg · wk 0.14 · n 93 · Phase 4 · secondary NCT04599855
  • -13.9 vs -9.7 56 mg · wk 0.14 · n 84 · Phase 4 · secondary NCT04599855
—Not reported
CGI-S, change (acute)-2 vs -1−1 vs placebo84 mg · wk 4 · n 113NCT02417064
30 other results
  • -2 vs -1 56 mg · wk 4 · n 115 · Phase 3 · secondary NCT02417064
  • -2 vs -2 wk 4 · n 111 · Phase 3 · secondary NCT02418585
  • -1 vs -1 wk 4 · n 121 · Phase 3 · secondary NCT03434041
  • -2.1 vs -1.9 wk 16 · n 327 · Phase 3 · secondary NCT04338321
  • -1.9 vs -1.4 wk 16 · n 327 · Phase 3 · secondary NCT04338321
  • -1.9 vs -1.7 wk 12 · n 327 · Phase 3 · secondary NCT04338321
  • -1.8 vs -1.3 wk 12 · n 327 · Phase 3 · secondary NCT04338321
  • -1.7 vs -1.4 wk 8 · n 327 · Phase 3 · secondary NCT04338321
  • -1.6 vs -1.2 wk 8 · n 327 · Phase 3 · secondary NCT04338321
  • -1.3 vs -1 wk 4 · n 327 · Phase 3 · secondary NCT04338321
  • -1.3 vs -0.9 wk 4 · n 327 · Phase 3 · secondary NCT04338321
  • -1 vs -0.7 wk 3 · n 327 · Phase 3 · secondary NCT04338321
  • -1 vs -0.7 wk 3 · n 327 · Phase 3 · secondary NCT04338321
  • -0.7 vs -0.5 wk 2 · n 327 · Phase 3 · secondary NCT04338321
  • -0.7 vs -0.5 wk 2 · n 327 · Phase 3 · secondary NCT04338321
  • -0.3 vs -0.2 wk 1 · n 327 · Phase 3 · secondary NCT04338321
  • -1 vs 0 wk 4 · n 71 · Phase 3 · secondary NCT02422186
  • -1 vs -1 84 mg · wk 4 · n 39 · Phase 2 · secondary NCT02918318
  • -1 vs -1 56 mg · wk 4 · n 33 · Phase 2 · secondary NCT02918318
  • -1 vs -1 28 mg · wk 4 · n 39 · Phase 2 · secondary NCT02918318
  • 4 vs 5 84 mg · wk 1 · n 12 · Phase 2 · secondary NCT01998958
  • 4 vs 5 84 mg · wk 1 · n 5 · Phase 2 · secondary NCT01998958
  • 4 vs 5 56 mg · wk 1 · n 11 · Phase 2 · secondary NCT01998958
  • 3 vs 5 56 mg · wk 1 · n 9 · Phase 2 · secondary NCT01998958
  • 5 vs 5 56 mg · wk 1 · n 9 · Phase 2 · secondary NCT01998958
  • 4 vs 5 28 mg · wk 1 · n 11 · Phase 2 · secondary NCT01998958
  • 4 vs 5 56 mg · wk 1 · n 3 · Phase 2 · secondary NCT01998958
  • 4 vs 5 28 mg · wk 1 · n 8 · Phase 2 · secondary NCT01998958
  • 4 vs 5 14 mg · wk 1 · n 11 · Phase 2 · secondary NCT01998958
  • 3 vs 5 14 mg · wk 1 · n 5 · Phase 2 · secondary NCT01998958
—Not reported
MADRS response53.1% vs 38.9%+14.2 vs placebo84 mg · wk 4 · n 98NCT02417064
67 other results
  • 47.8% vs 37.2% 84 mg · wk 4 · n 113 · Phase 3 · secondary NCT02417064
  • 54.1% vs 38.9% 56 mg · wk 4 · n 111 · Phase 3 · secondary NCT02417064
  • 53% vs 37.2% 56 mg · wk 4 · n 115 · Phase 3 · secondary NCT02417064
  • 63.4% vs 49.5% wk 4 · n 112 · Phase 3 · secondary NCT02418585
  • 6.5% vs 1.6% wk 4 · n 124 · Phase 3 · secondary NCT03434041
  • 19.3% vs 16% wk 4 · n 109 · Phase 3 · secondary NCT03434041
  • 10.5% vs 6.4% wk 1.14 · n 114 · Phase 3 · secondary NCT02418585
  • 7.9% vs 4.6% wk 0.29 · n 114 · Phase 3 · secondary NCT02418585
  • 23.9% vs 12.5% wk 4 · n 71 · Phase 3 · secondary NCT02422186
  • 66.7% vs 63.6% 84 mg · wk 11.4286 · n 27 · Phase 2 · secondary NCT02133001
  • 43.6% vs 37.5% 84 mg · wk 4 · n 41 · Phase 2 · secondary NCT02918318
  • 20.5% vs 29.7% 84 mg · wk 3.14 · n 41 · Phase 2 · secondary NCT02918318
  • 15% vs 18.2% 84 mg · wk 2.14 · n 41 · Phase 2 · secondary NCT02918318
  • 9.8% vs 3.8% 84 mg · wk 1.14 · n 41 · Phase 2 · secondary NCT02918318
  • 10% vs 9% 84 mg · wk 0.29 · n 41 · Phase 2 · secondary NCT02918318
  • 54.3% vs 29% 84 mg · wk 0.29 · n 35 · Phase 2 · secondary NCT02133001
  • 25.7% vs 12.9% 84 mg · wk 0.14 · n 35 · Phase 2 · secondary NCT02133001
  • 35.3% vs 37.5% 56 mg · wk 4 · n 40 · Phase 2 · secondary NCT02918318
  • 13.9% vs 29.7% 56 mg · wk 3.14 · n 40 · Phase 2 · secondary NCT02918318
  • 8.3% vs 18.2% 56 mg · wk 2.14 · n 40 · Phase 2 · secondary NCT02918318
  • 2.6% vs 3.8% 56 mg · wk 1.14 · n 40 · Phase 2 · secondary NCT02918318
  • 13.2% vs 9% 56 mg · wk 0.29 · n 40 · Phase 2 · secondary NCT02918318
  • 33.3% vs 37.5% 28 mg · wk 4 · n 41 · Phase 2 · secondary NCT02918318
  • 23.1% vs 29.7% 28 mg · wk 3.14 · n 41 · Phase 2 · secondary NCT02918318
  • 17.5% vs 18.2% 28 mg · wk 2.14 · n 41 · Phase 2 · secondary NCT02918318
  • 2.4% vs 3.8% 28 mg · wk 1.14 · n 41 · Phase 2 · secondary NCT02918318
  • 22% vs 9% 28 mg · wk 0.29 · n 41 · Phase 2 · secondary NCT02918318
  • 30% vs 15.4% 84 mg · wk 2 · n 10 · Phase 2 · secondary NCT01998958
  • 25% vs 15.4% 84 mg · wk 2 · n 12 · Phase 2 · secondary NCT01998958
  • 41.7% vs 6.1% 84 mg · wk 1.14 · n 12 · Phase 2 · secondary NCT01998958
  • 20% vs 0% 84 mg · wk 1.14 · n 5 · Phase 2 · secondary NCT01998958
  • 41.7% vs 3% 84 mg · wk 0.29 · n 12 · Phase 2 · secondary NCT01998958
  • 40% vs 0% 84 mg · wk 0.29 · n 5 · Phase 2 · secondary NCT01998958
  • 58.3% vs 18.2% 84 mg · wk 0.14 · n 12 · Phase 2 · secondary NCT01998958
  • 40% vs 16.7% 84 mg · wk 0.14 · n 5 · Phase 2 · secondary NCT01998958
  • 9.1% vs 15.4% 56 mg · wk 2 · n 11 · Phase 2 · secondary NCT01998958
  • 22.2% vs 15.4% 56 mg · wk 2 · n 9 · Phase 2 · secondary NCT01998958
  • 9.1% vs 15.4% 56 mg · wk 2 · n 11 · Phase 2 · secondary NCT01998958
  • 22.2% vs 15.4% 56 mg · wk 2 · n 9 · Phase 2 · secondary NCT01998958
  • 18.2% vs 6.1% 56 mg · wk 1.14 · n 11 · Phase 2 · secondary NCT01998958
  • 22.2% vs 6.1% 56 mg · wk 1.14 · n 9 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 56 mg · wk 1.14 · n 9 · Phase 2 · secondary NCT01998958
  • 27.3% vs 3% 56 mg · wk 0.29 · n 11 · Phase 2 · secondary NCT01998958
  • 44.4% vs 3% 56 mg · wk 0.29 · n 9 · Phase 2 · secondary NCT01998958
  • 11.1% vs 0% 56 mg · wk 0.29 · n 9 · Phase 2 · secondary NCT01998958
  • 36.4% vs 18.2% 56 mg · wk 0.14 · n 11 · Phase 2 · secondary NCT01998958
  • 44.4% vs 18.2% 56 mg · wk 0.14 · n 9 · Phase 2 · secondary NCT01998958
  • 22.2% vs 16.7% 56 mg · wk 0.14 · n 9 · Phase 2 · secondary NCT01998958
  • 12.5% vs 15.4% 28 mg · wk 2 · n 8 · Phase 2 · secondary NCT01998958
  • 12.5% vs 15.4% 28 mg · wk 2 · n 8 · Phase 2 · secondary NCT01998958
  • 9.1% vs 6.1% 28 mg · wk 1.14 · n 11 · Phase 2 · secondary NCT01998958
  • 12.5% vs 0% 28 mg · wk 1.14 · n 8 · Phase 2 · secondary NCT01998958
  • 36.4% vs 3% 28 mg · wk 0.29 · n 11 · Phase 2 · secondary NCT01998958
  • 54.5% vs 18.2% 28 mg · wk 0.14 · n 11 · Phase 2 · secondary NCT01998958
  • 33.3% vs 0% 56 mg · wk 1.14 · n 3 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 56 mg · wk 0.29 · n 3 · Phase 2 · secondary NCT01998958
  • 0% vs 16.7% 56 mg · wk 0.14 · n 3 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 28 mg · wk 0.29 · n 8 · Phase 2 · secondary NCT01998958
  • 12.5% vs 16.7% 28 mg · wk 0.14 · n 8 · Phase 2 · secondary NCT01998958
  • 18.2% vs 15.4% 14 mg · wk 2 · n 11 · Phase 2 · secondary NCT01998958
  • 18.2% vs 15.4% 14 mg · wk 2 · n 11 · Phase 2 · secondary NCT01998958
  • 18.2% vs 6.1% 14 mg · wk 1.14 · n 11 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 14 mg · wk 1.14 · n 5 · Phase 2 · secondary NCT01998958
  • 36.4% vs 3% 14 mg · wk 0.29 · n 11 · Phase 2 · secondary NCT01998958
  • 80% vs 0% 14 mg · wk 0.29 · n 5 · Phase 2 · secondary NCT01998958
  • 36.4% vs 18.2% 14 mg · wk 0.14 · n 11 · Phase 2 · secondary NCT01998958
  • 60% vs 16.7% 14 mg · wk 0.14 · n 5 · Phase 2 · secondary NCT01998958
—Not reported
MADRS remission27.1% vs 17.6%vs Quetiapine Extended Release (XR) + Oral ADwk 8 · n 336NCT04338321
67 other results
  • 36.8% vs 32.7% 84 mg · wk 3.14 · n 114 · Phase 3 · secondary NCT03097133
  • 36.6% vs 22.3% 84 mg · wk 3.14 · n 112 · Phase 3 · secondary NCT03039192
  • 25.4% vs 28.3% 84 mg · wk 2.57 · n 114 · Phase 3 · secondary NCT03097133
  • 37.5% vs 26.8% 84 mg · wk 2.57 · n 112 · Phase 3 · secondary NCT03039192
  • 31.6% vs 25.7% 84 mg · wk 2.14 · n 114 · Phase 3 · secondary NCT03097133
  • 33.9% vs 25.9% 84 mg · wk 2.14 · n 112 · Phase 3 · secondary NCT03039192
  • 28.1% vs 23% 84 mg · wk 1.57 · n 114 · Phase 3 · secondary NCT03097133
  • 29.5% vs 23.2% 84 mg · wk 1.57 · n 112 · Phase 3 · secondary NCT03039192
  • 24.6% vs 20.4% 84 mg · wk 1.14 · n 114 · Phase 3 · secondary NCT03097133
  • 26.8% vs 20.5% 84 mg · wk 1.14 · n 112 · Phase 3 · secondary NCT03039192
  • 22.8% vs 17.7% 84 mg · wk 0.57 · n 114 · Phase 3 · secondary NCT03097133
  • 25% vs 11.6% 84 mg · wk 0.57 · n 112 · Phase 3 · secondary NCT03039192
  • 21.9% vs 10.6% 84 mg · wk 0.29 · n 114 · Phase 3 · secondary NCT03097133
  • 18.8% vs 8.9% 84 mg · wk 0.29 · n 112 · Phase 3 · secondary NCT03039192
  • 10.7% vs 8% 84 mg · wk 0.14 · n 112 · Phase 3 · secondary NCT03039192
  • 38.8% vs 30.6% 84 mg · wk 4 · n 98 · Phase 3 · secondary NCT02417064
  • 35.4% vs 29.2% 84 mg · wk 4 · n 113 · Phase 3 · secondary NCT02417064
  • 36% vs 30.6% 56 mg · wk 4 · n 111 · Phase 3 · secondary NCT02417064
  • 34.8% vs 29.2% 56 mg · wk 4 · n 115 · Phase 3 · secondary NCT02417064
  • 48.2% vs 30.3% wk 4 · n 112 · Phase 3 · secondary NCT02418585
  • 12.8% vs 10.4% wk 4 · n 109 · Phase 3 · secondary NCT03434041
  • 15.5% vs 6.3% wk 4 · n 71 · Phase 3 · secondary NCT02422186
  • 23.1% vs 20.8% 84 mg · wk 4 · n 41 · Phase 2 · secondary NCT02918318
  • 7.7% vs 14.9% 84 mg · wk 3.14 · n 41 · Phase 2 · secondary NCT02918318
  • 10% vs 3.9% 84 mg · wk 2.14 · n 41 · Phase 2 · secondary NCT02918318
  • 4.9% vs 1.3% 84 mg · wk 1.14 · n 41 · Phase 2 · secondary NCT02918318
  • 7.5% vs 3.8% 84 mg · wk 0.29 · n 41 · Phase 2 · secondary NCT02918318
  • 11.8% vs 20.8% 56 mg · wk 4 · n 40 · Phase 2 · secondary NCT02918318
  • 5.6% vs 14.9% 56 mg · wk 3.14 · n 40 · Phase 2 · secondary NCT02918318
  • 2.8% vs 3.9% 56 mg · wk 2.14 · n 40 · Phase 2 · secondary NCT02918318
  • 0% vs 1.3% 56 mg · wk 1.14 · n 40 · Phase 2 · secondary NCT02918318
  • 0% vs 3.8% 56 mg · wk 0.29 · n 40 · Phase 2 · secondary NCT02918318
  • 23.1% vs 20.8% 28 mg · wk 4 · n 41 · Phase 2 · secondary NCT02918318
  • 10.3% vs 14.9% 28 mg · wk 3.14 · n 41 · Phase 2 · secondary NCT02918318
  • 7.5% vs 3.9% 28 mg · wk 2.14 · n 41 · Phase 2 · secondary NCT02918318
  • 2.4% vs 1.3% 28 mg · wk 1.14 · n 41 · Phase 2 · secondary NCT02918318
  • 9.8% vs 3.8% 28 mg · wk 0.29 · n 41 · Phase 2 · secondary NCT02918318
  • 25% vs 3% 84 mg · wk 1.14 · n 12 · Phase 2 · secondary NCT01998958
  • 20% vs 0% 84 mg · wk 1.14 · n 5 · Phase 2 · secondary NCT01998958
  • 25% vs 0% 84 mg · wk 0.29 · n 12 · Phase 2 · secondary NCT01998958
  • 20% vs 0% 84 mg · wk 0.29 · n 5 · Phase 2 · secondary NCT01998958
  • 25% vs 3% 84 mg · wk 0.14 · n 12 · Phase 2 · secondary NCT01998958
  • 40% vs 16.7% 84 mg · wk 0.14 · n 5 · Phase 2 · secondary NCT01998958
  • 9.1% vs 3% 56 mg · wk 1.14 · n 11 · Phase 2 · secondary NCT01998958
  • 22.2% vs 3% 56 mg · wk 1.14 · n 9 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 56 mg · wk 1.14 · n 9 · Phase 2 · secondary NCT01998958
  • 18.2% vs 0% 56 mg · wk 0.29 · n 11 · Phase 2 · secondary NCT01998958
  • 33.3% vs 0% 56 mg · wk 0.29 · n 9 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 56 mg · wk 0.29 · n 9 · Phase 2 · secondary NCT01998958
  • 18.2% vs 3% 56 mg · wk 0.14 · n 11 · Phase 2 · secondary NCT01998958
  • 33.3% vs 3% 56 mg · wk 0.14 · n 9 · Phase 2 · secondary NCT01998958
  • 0% vs 16.7% 56 mg · wk 0.14 · n 9 · Phase 2 · secondary NCT01998958
  • 9.1% vs 3% 28 mg · wk 1.14 · n 11 · Phase 2 · secondary NCT01998958
  • 12.5% vs 0% 28 mg · wk 1.14 · n 8 · Phase 2 · secondary NCT01998958
  • 36.4% vs 0% 28 mg · wk 0.29 · n 11 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 28 mg · wk 0.29 · n 8 · Phase 2 · secondary NCT01998958
  • 27.3% vs 3% 28 mg · wk 0.14 · n 11 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 56 mg · wk 1.14 · n 3 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 56 mg · wk 0.29 · n 3 · Phase 2 · secondary NCT01998958
  • 12.5% vs 16.7% 28 mg · wk 0.14 · n 8 · Phase 2 · secondary NCT01998958
  • 18.2% vs 3% 14 mg · wk 1.14 · n 11 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 14 mg · wk 1.14 · n 5 · Phase 2 · secondary NCT01998958
  • 27.3% vs 0% 14 mg · wk 0.29 · n 11 · Phase 2 · secondary NCT01998958
  • 80% vs 0% 14 mg · wk 0.29 · n 5 · Phase 2 · secondary NCT01998958
  • 36.4% vs 3% 14 mg · wk 0.14 · n 11 · Phase 2 · secondary NCT01998958
  • 0% vs 16.7% 56 mg · wk 0.14 · n 3 · Phase 2 · secondary NCT01998958
  • 60% vs 16.7% 14 mg · wk 0.14 · n 5 · Phase 2 · secondary NCT01998958
—Not reported
Relapse (% of patients)—Trial running · NCT07153406—Not reported

MADRS, change (acute)

Esketamine
-15.7 vs -12.4−3.3 vs placebo84 mg · wk 0.14 · n 113NCT03097133
64 other results
  • -16.4 vs -12.8 84 mg · wk 0.14 · n 111 · Phase 3 · primary NCT03039192
  • -18.8 vs -14.8 84 mg · wk 4 · n 98 · Phase 3 · primary NCT02417064
  • -17.4 vs -14.3 84 mg · wk 4 · n 113 · Phase 3 · primary NCT02417064
  • -19 vs -14.8 56 mg · wk 4 · n 111 · Phase 3 · primary NCT02417064
  • -18.3 vs -14.3 56 mg · wk 4 · n 115 · Phase 3 · primary NCT02417064
  • -21.4 vs -17 wk 4 · n 101 · Phase 3 · primary NCT02418585
  • -19.6 vs -16.3 wk 4 · n 112 · Phase 3 · primary NCT02418585
  • -10.1 vs -8.1 wk 4 · n 109 · Phase 3 · primary NCT03434041
  • -10 vs -6.3 wk 4 · n 63 · Phase 3 · primary NCT02422186
  • -9.3 vs -5.6 wk 4 · n 71 · Phase 3 · primary NCT02422186
  • -29.5 vs -25.8 84 mg · wk 3.57 · n 112 · Phase 3 · secondary NCT03039192
  • -24.5 vs -22 84 mg · wk 3.14 · n 114 · Phase 3 · secondary NCT03097133
  • -24 vs -21.6 84 mg · wk 3.14 · n 112 · Phase 3 · secondary NCT03039192
  • -23.1 vs -21.4 84 mg · wk 2.57 · n 114 · Phase 3 · secondary NCT03097133
  • -23.9 vs -21.4 84 mg · wk 2.57 · n 112 · Phase 3 · secondary NCT03039192
  • -23.4 vs -20 84 mg · wk 2.14 · n 114 · Phase 3 · secondary NCT03097133
  • -22.3 vs -20.4 84 mg · wk 2.14 · n 112 · Phase 3 · secondary NCT03039192
  • -21.3 vs -19.5 84 mg · wk 1.57 · n 114 · Phase 3 · secondary NCT03097133
  • -21.8 vs -19 84 mg · wk 1.57 · n 112 · Phase 3 · secondary NCT03039192
  • -20.1 vs -17.4 84 mg · wk 1.14 · n 114 · Phase 3 · secondary NCT03097133
  • -19.7 vs -17.4 84 mg · wk 1.14 · n 112 · Phase 3 · secondary NCT03039192
  • -17.7 vs -15.7 84 mg · wk 0.57 · n 114 · Phase 3 · secondary NCT03097133
  • -19.1 vs -14.5 84 mg · wk 0.57 · n 112 · Phase 3 · secondary NCT03039192
  • -16 vs -12.4 84 mg · wk 0.29 · n 114 · Phase 3 · secondary NCT03097133
  • -16.4 vs -12.9 84 mg · wk 0.29 · n 112 · Phase 3 · secondary NCT03039192
  • -13.5 vs -10.9 84 mg · wk 0.14 · n 112 · Phase 3 · secondary NCT03039192
  • -8 vs -4.4 wk 0.14 · n 123 · Phase 3 · secondary NCT03434041
  • -19.6 vs -17.8 wk 16 · n 327 · Phase 3 · secondary NCT04338321
  • -18.1 vs -13.7 wk 16 · n 327 · Phase 3 · secondary NCT04338321
  • -19 vs -17.1 wk 14 · n 327 · Phase 3 · secondary NCT04338321
  • -17.6 vs -13.2 wk 14 · n 327 · Phase 3 · secondary NCT04338321
  • -18.4 vs -16.7 wk 12 · n 327 · Phase 3 · secondary NCT04338321
  • -17.1 vs -13.1 wk 12 · n 327 · Phase 3 · secondary NCT04338321
  • -18.2 vs -16.2 wk 10 · n 327 · Phase 3 · secondary NCT04338321
  • -16.9 vs -12.8 wk 10 · n 327 · Phase 3 · secondary NCT04338321
  • -16.4 vs -14.3 wk 8 · n 327 · Phase 3 · secondary NCT04338321
  • -15.7 vs -12 wk 8 · n 327 · Phase 3 · secondary NCT04338321
  • -14.9 vs -12.2 wk 6 · n 327 · Phase 3 · secondary NCT04338321
  • -14.5 vs -10.7 wk 6 · n 327 · Phase 3 · secondary NCT04338321
  • -12.8 vs -9.8 wk 4 · n 327 · Phase 3 · secondary NCT04338321
  • -12.6 vs -8.9 wk 4 · n 327 · Phase 3 · secondary NCT04338321
  • -9 vs -6.1 wk 2 · n 327 · Phase 3 · secondary NCT04338321
  • -9 vs -5.8 wk 2 · n 327 · Phase 3 · secondary NCT04338321
  • -5.3 vs -3.7 wk 1 · n 327 · Phase 3 · secondary NCT04338321
  • -13.9 vs -7 84 mg · wk 4 · n 89 · Phase 4 · primary NCT04599855
  • -15.1 vs -15.3 84 mg · wk 4 · n 39 · Phase 2 · primary NCT02918318
  • -12.7 vs -7 56 mg · wk 4 · n 82 · Phase 4 · primary NCT04599855
  • -15.3 vs -4.9 84 mg · wk 1 · n 12 · Phase 2 · primary NCT01998958
  • -13.4 vs -9.1 84 mg · wk 0.0238 · n 35 · Phase 2 · primary NCT02133001
  • -14.5 vs -15.3 56 mg · wk 4 · n 34 · Phase 2 · primary NCT02918318
  • -15.2 vs -15.3 28 mg · wk 4 · n 39 · Phase 2 · primary NCT02918318
  • -11.4 vs -4.5 84 mg · wk 1 · n 5 · Phase 2 · primary NCT01998958
  • -12.4 vs -4.9 56 mg · wk 1 · n 11 · Phase 2 · primary NCT01998958
  • -10.3 vs -4.9 56 mg · wk 1 · n 9 · Phase 2 · primary NCT01998958
  • -8.9 vs -4.5 56 mg · wk 1 · n 9 · Phase 2 · primary NCT01998958
  • -9.8 vs -4.9 28 mg · wk 1 · n 11 · Phase 2 · primary NCT01998958
  • -7.6 vs -4.5 28 mg · wk 1 · n 8 · Phase 2 · primary NCT01998958
  • -4.8 vs -4.9 14 mg · wk 1 · n 11 · Phase 2 · primary NCT01998958
  • -1.2 vs -4.5 56 mg · wk 1 · n 3 · Phase 2 · primary NCT01998958
  • -6.6 vs -4.5 14 mg · wk 1 · n 5 · Phase 2 · primary NCT01998958
  • -26.4 vs -23 84 mg · wk 3.4286 · n 35 · Phase 2 · secondary NCT02133001
  • -19.3 vs -12.8 84 mg · wk 0.1429 · n 35 · Phase 2 · secondary NCT02133001
  • -13 vs -9.7 84 mg · wk 0.14 · n 93 · Phase 4 · secondary NCT04599855
  • -13.9 vs -9.7 56 mg · wk 0.14 · n 84 · Phase 4 · secondary NCT04599855
SP-101
—Not reported

CGI-S, change (acute)

Esketamine
-2 vs -1−1 vs placebo84 mg · wk 4 · n 113NCT02417064
30 other results
  • -2 vs -1 56 mg · wk 4 · n 115 · Phase 3 · secondary NCT02417064
  • -2 vs -2 wk 4 · n 111 · Phase 3 · secondary NCT02418585
  • -1 vs -1 wk 4 · n 121 · Phase 3 · secondary NCT03434041
  • -2.1 vs -1.9 wk 16 · n 327 · Phase 3 · secondary NCT04338321
  • -1.9 vs -1.4 wk 16 · n 327 · Phase 3 · secondary NCT04338321
  • -1.9 vs -1.7 wk 12 · n 327 · Phase 3 · secondary NCT04338321
  • -1.8 vs -1.3 wk 12 · n 327 · Phase 3 · secondary NCT04338321
  • -1.7 vs -1.4 wk 8 · n 327 · Phase 3 · secondary NCT04338321
  • -1.6 vs -1.2 wk 8 · n 327 · Phase 3 · secondary NCT04338321
  • -1.3 vs -1 wk 4 · n 327 · Phase 3 · secondary NCT04338321
  • -1.3 vs -0.9 wk 4 · n 327 · Phase 3 · secondary NCT04338321
  • -1 vs -0.7 wk 3 · n 327 · Phase 3 · secondary NCT04338321
  • -1 vs -0.7 wk 3 · n 327 · Phase 3 · secondary NCT04338321
  • -0.7 vs -0.5 wk 2 · n 327 · Phase 3 · secondary NCT04338321
  • -0.7 vs -0.5 wk 2 · n 327 · Phase 3 · secondary NCT04338321
  • -0.3 vs -0.2 wk 1 · n 327 · Phase 3 · secondary NCT04338321
  • -1 vs 0 wk 4 · n 71 · Phase 3 · secondary NCT02422186
  • -1 vs -1 84 mg · wk 4 · n 39 · Phase 2 · secondary NCT02918318
  • -1 vs -1 56 mg · wk 4 · n 33 · Phase 2 · secondary NCT02918318
  • -1 vs -1 28 mg · wk 4 · n 39 · Phase 2 · secondary NCT02918318
  • 4 vs 5 84 mg · wk 1 · n 12 · Phase 2 · secondary NCT01998958
  • 4 vs 5 84 mg · wk 1 · n 5 · Phase 2 · secondary NCT01998958
  • 4 vs 5 56 mg · wk 1 · n 11 · Phase 2 · secondary NCT01998958
  • 3 vs 5 56 mg · wk 1 · n 9 · Phase 2 · secondary NCT01998958
  • 5 vs 5 56 mg · wk 1 · n 9 · Phase 2 · secondary NCT01998958
  • 4 vs 5 28 mg · wk 1 · n 11 · Phase 2 · secondary NCT01998958
  • 4 vs 5 56 mg · wk 1 · n 3 · Phase 2 · secondary NCT01998958
  • 4 vs 5 28 mg · wk 1 · n 8 · Phase 2 · secondary NCT01998958
  • 4 vs 5 14 mg · wk 1 · n 11 · Phase 2 · secondary NCT01998958
  • 3 vs 5 14 mg · wk 1 · n 5 · Phase 2 · secondary NCT01998958
SP-101
—Not reported

MADRS response

Esketamine
53.1% vs 38.9%+14.2 vs placebo84 mg · wk 4 · n 98NCT02417064
67 other results
  • 47.8% vs 37.2% 84 mg · wk 4 · n 113 · Phase 3 · secondary NCT02417064
  • 54.1% vs 38.9% 56 mg · wk 4 · n 111 · Phase 3 · secondary NCT02417064
  • 53% vs 37.2% 56 mg · wk 4 · n 115 · Phase 3 · secondary NCT02417064
  • 63.4% vs 49.5% wk 4 · n 112 · Phase 3 · secondary NCT02418585
  • 6.5% vs 1.6% wk 4 · n 124 · Phase 3 · secondary NCT03434041
  • 19.3% vs 16% wk 4 · n 109 · Phase 3 · secondary NCT03434041
  • 10.5% vs 6.4% wk 1.14 · n 114 · Phase 3 · secondary NCT02418585
  • 7.9% vs 4.6% wk 0.29 · n 114 · Phase 3 · secondary NCT02418585
  • 23.9% vs 12.5% wk 4 · n 71 · Phase 3 · secondary NCT02422186
  • 66.7% vs 63.6% 84 mg · wk 11.4286 · n 27 · Phase 2 · secondary NCT02133001
  • 43.6% vs 37.5% 84 mg · wk 4 · n 41 · Phase 2 · secondary NCT02918318
  • 20.5% vs 29.7% 84 mg · wk 3.14 · n 41 · Phase 2 · secondary NCT02918318
  • 15% vs 18.2% 84 mg · wk 2.14 · n 41 · Phase 2 · secondary NCT02918318
  • 9.8% vs 3.8% 84 mg · wk 1.14 · n 41 · Phase 2 · secondary NCT02918318
  • 10% vs 9% 84 mg · wk 0.29 · n 41 · Phase 2 · secondary NCT02918318
  • 54.3% vs 29% 84 mg · wk 0.29 · n 35 · Phase 2 · secondary NCT02133001
  • 25.7% vs 12.9% 84 mg · wk 0.14 · n 35 · Phase 2 · secondary NCT02133001
  • 35.3% vs 37.5% 56 mg · wk 4 · n 40 · Phase 2 · secondary NCT02918318
  • 13.9% vs 29.7% 56 mg · wk 3.14 · n 40 · Phase 2 · secondary NCT02918318
  • 8.3% vs 18.2% 56 mg · wk 2.14 · n 40 · Phase 2 · secondary NCT02918318
  • 2.6% vs 3.8% 56 mg · wk 1.14 · n 40 · Phase 2 · secondary NCT02918318
  • 13.2% vs 9% 56 mg · wk 0.29 · n 40 · Phase 2 · secondary NCT02918318
  • 33.3% vs 37.5% 28 mg · wk 4 · n 41 · Phase 2 · secondary NCT02918318
  • 23.1% vs 29.7% 28 mg · wk 3.14 · n 41 · Phase 2 · secondary NCT02918318
  • 17.5% vs 18.2% 28 mg · wk 2.14 · n 41 · Phase 2 · secondary NCT02918318
  • 2.4% vs 3.8% 28 mg · wk 1.14 · n 41 · Phase 2 · secondary NCT02918318
  • 22% vs 9% 28 mg · wk 0.29 · n 41 · Phase 2 · secondary NCT02918318
  • 30% vs 15.4% 84 mg · wk 2 · n 10 · Phase 2 · secondary NCT01998958
  • 25% vs 15.4% 84 mg · wk 2 · n 12 · Phase 2 · secondary NCT01998958
  • 41.7% vs 6.1% 84 mg · wk 1.14 · n 12 · Phase 2 · secondary NCT01998958
  • 20% vs 0% 84 mg · wk 1.14 · n 5 · Phase 2 · secondary NCT01998958
  • 41.7% vs 3% 84 mg · wk 0.29 · n 12 · Phase 2 · secondary NCT01998958
  • 40% vs 0% 84 mg · wk 0.29 · n 5 · Phase 2 · secondary NCT01998958
  • 58.3% vs 18.2% 84 mg · wk 0.14 · n 12 · Phase 2 · secondary NCT01998958
  • 40% vs 16.7% 84 mg · wk 0.14 · n 5 · Phase 2 · secondary NCT01998958
  • 9.1% vs 15.4% 56 mg · wk 2 · n 11 · Phase 2 · secondary NCT01998958
  • 22.2% vs 15.4% 56 mg · wk 2 · n 9 · Phase 2 · secondary NCT01998958
  • 9.1% vs 15.4% 56 mg · wk 2 · n 11 · Phase 2 · secondary NCT01998958
  • 22.2% vs 15.4% 56 mg · wk 2 · n 9 · Phase 2 · secondary NCT01998958
  • 18.2% vs 6.1% 56 mg · wk 1.14 · n 11 · Phase 2 · secondary NCT01998958
  • 22.2% vs 6.1% 56 mg · wk 1.14 · n 9 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 56 mg · wk 1.14 · n 9 · Phase 2 · secondary NCT01998958
  • 27.3% vs 3% 56 mg · wk 0.29 · n 11 · Phase 2 · secondary NCT01998958
  • 44.4% vs 3% 56 mg · wk 0.29 · n 9 · Phase 2 · secondary NCT01998958
  • 11.1% vs 0% 56 mg · wk 0.29 · n 9 · Phase 2 · secondary NCT01998958
  • 36.4% vs 18.2% 56 mg · wk 0.14 · n 11 · Phase 2 · secondary NCT01998958
  • 44.4% vs 18.2% 56 mg · wk 0.14 · n 9 · Phase 2 · secondary NCT01998958
  • 22.2% vs 16.7% 56 mg · wk 0.14 · n 9 · Phase 2 · secondary NCT01998958
  • 12.5% vs 15.4% 28 mg · wk 2 · n 8 · Phase 2 · secondary NCT01998958
  • 12.5% vs 15.4% 28 mg · wk 2 · n 8 · Phase 2 · secondary NCT01998958
  • 9.1% vs 6.1% 28 mg · wk 1.14 · n 11 · Phase 2 · secondary NCT01998958
  • 12.5% vs 0% 28 mg · wk 1.14 · n 8 · Phase 2 · secondary NCT01998958
  • 36.4% vs 3% 28 mg · wk 0.29 · n 11 · Phase 2 · secondary NCT01998958
  • 54.5% vs 18.2% 28 mg · wk 0.14 · n 11 · Phase 2 · secondary NCT01998958
  • 33.3% vs 0% 56 mg · wk 1.14 · n 3 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 56 mg · wk 0.29 · n 3 · Phase 2 · secondary NCT01998958
  • 0% vs 16.7% 56 mg · wk 0.14 · n 3 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 28 mg · wk 0.29 · n 8 · Phase 2 · secondary NCT01998958
  • 12.5% vs 16.7% 28 mg · wk 0.14 · n 8 · Phase 2 · secondary NCT01998958
  • 18.2% vs 15.4% 14 mg · wk 2 · n 11 · Phase 2 · secondary NCT01998958
  • 18.2% vs 15.4% 14 mg · wk 2 · n 11 · Phase 2 · secondary NCT01998958
  • 18.2% vs 6.1% 14 mg · wk 1.14 · n 11 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 14 mg · wk 1.14 · n 5 · Phase 2 · secondary NCT01998958
  • 36.4% vs 3% 14 mg · wk 0.29 · n 11 · Phase 2 · secondary NCT01998958
  • 80% vs 0% 14 mg · wk 0.29 · n 5 · Phase 2 · secondary NCT01998958
  • 36.4% vs 18.2% 14 mg · wk 0.14 · n 11 · Phase 2 · secondary NCT01998958
  • 60% vs 16.7% 14 mg · wk 0.14 · n 5 · Phase 2 · secondary NCT01998958
SP-101
—Not reported

MADRS remission

Esketamine
27.1% vs 17.6%vs Quetiapine Extended Release (XR) + Oral ADwk 8 · n 336NCT04338321
67 other results
  • 36.8% vs 32.7% 84 mg · wk 3.14 · n 114 · Phase 3 · secondary NCT03097133
  • 36.6% vs 22.3% 84 mg · wk 3.14 · n 112 · Phase 3 · secondary NCT03039192
  • 25.4% vs 28.3% 84 mg · wk 2.57 · n 114 · Phase 3 · secondary NCT03097133
  • 37.5% vs 26.8% 84 mg · wk 2.57 · n 112 · Phase 3 · secondary NCT03039192
  • 31.6% vs 25.7% 84 mg · wk 2.14 · n 114 · Phase 3 · secondary NCT03097133
  • 33.9% vs 25.9% 84 mg · wk 2.14 · n 112 · Phase 3 · secondary NCT03039192
  • 28.1% vs 23% 84 mg · wk 1.57 · n 114 · Phase 3 · secondary NCT03097133
  • 29.5% vs 23.2% 84 mg · wk 1.57 · n 112 · Phase 3 · secondary NCT03039192
  • 24.6% vs 20.4% 84 mg · wk 1.14 · n 114 · Phase 3 · secondary NCT03097133
  • 26.8% vs 20.5% 84 mg · wk 1.14 · n 112 · Phase 3 · secondary NCT03039192
  • 22.8% vs 17.7% 84 mg · wk 0.57 · n 114 · Phase 3 · secondary NCT03097133
  • 25% vs 11.6% 84 mg · wk 0.57 · n 112 · Phase 3 · secondary NCT03039192
  • 21.9% vs 10.6% 84 mg · wk 0.29 · n 114 · Phase 3 · secondary NCT03097133
  • 18.8% vs 8.9% 84 mg · wk 0.29 · n 112 · Phase 3 · secondary NCT03039192
  • 10.7% vs 8% 84 mg · wk 0.14 · n 112 · Phase 3 · secondary NCT03039192
  • 38.8% vs 30.6% 84 mg · wk 4 · n 98 · Phase 3 · secondary NCT02417064
  • 35.4% vs 29.2% 84 mg · wk 4 · n 113 · Phase 3 · secondary NCT02417064
  • 36% vs 30.6% 56 mg · wk 4 · n 111 · Phase 3 · secondary NCT02417064
  • 34.8% vs 29.2% 56 mg · wk 4 · n 115 · Phase 3 · secondary NCT02417064
  • 48.2% vs 30.3% wk 4 · n 112 · Phase 3 · secondary NCT02418585
  • 12.8% vs 10.4% wk 4 · n 109 · Phase 3 · secondary NCT03434041
  • 15.5% vs 6.3% wk 4 · n 71 · Phase 3 · secondary NCT02422186
  • 23.1% vs 20.8% 84 mg · wk 4 · n 41 · Phase 2 · secondary NCT02918318
  • 7.7% vs 14.9% 84 mg · wk 3.14 · n 41 · Phase 2 · secondary NCT02918318
  • 10% vs 3.9% 84 mg · wk 2.14 · n 41 · Phase 2 · secondary NCT02918318
  • 4.9% vs 1.3% 84 mg · wk 1.14 · n 41 · Phase 2 · secondary NCT02918318
  • 7.5% vs 3.8% 84 mg · wk 0.29 · n 41 · Phase 2 · secondary NCT02918318
  • 11.8% vs 20.8% 56 mg · wk 4 · n 40 · Phase 2 · secondary NCT02918318
  • 5.6% vs 14.9% 56 mg · wk 3.14 · n 40 · Phase 2 · secondary NCT02918318
  • 2.8% vs 3.9% 56 mg · wk 2.14 · n 40 · Phase 2 · secondary NCT02918318
  • 0% vs 1.3% 56 mg · wk 1.14 · n 40 · Phase 2 · secondary NCT02918318
  • 0% vs 3.8% 56 mg · wk 0.29 · n 40 · Phase 2 · secondary NCT02918318
  • 23.1% vs 20.8% 28 mg · wk 4 · n 41 · Phase 2 · secondary NCT02918318
  • 10.3% vs 14.9% 28 mg · wk 3.14 · n 41 · Phase 2 · secondary NCT02918318
  • 7.5% vs 3.9% 28 mg · wk 2.14 · n 41 · Phase 2 · secondary NCT02918318
  • 2.4% vs 1.3% 28 mg · wk 1.14 · n 41 · Phase 2 · secondary NCT02918318
  • 9.8% vs 3.8% 28 mg · wk 0.29 · n 41 · Phase 2 · secondary NCT02918318
  • 25% vs 3% 84 mg · wk 1.14 · n 12 · Phase 2 · secondary NCT01998958
  • 20% vs 0% 84 mg · wk 1.14 · n 5 · Phase 2 · secondary NCT01998958
  • 25% vs 0% 84 mg · wk 0.29 · n 12 · Phase 2 · secondary NCT01998958
  • 20% vs 0% 84 mg · wk 0.29 · n 5 · Phase 2 · secondary NCT01998958
  • 25% vs 3% 84 mg · wk 0.14 · n 12 · Phase 2 · secondary NCT01998958
  • 40% vs 16.7% 84 mg · wk 0.14 · n 5 · Phase 2 · secondary NCT01998958
  • 9.1% vs 3% 56 mg · wk 1.14 · n 11 · Phase 2 · secondary NCT01998958
  • 22.2% vs 3% 56 mg · wk 1.14 · n 9 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 56 mg · wk 1.14 · n 9 · Phase 2 · secondary NCT01998958
  • 18.2% vs 0% 56 mg · wk 0.29 · n 11 · Phase 2 · secondary NCT01998958
  • 33.3% vs 0% 56 mg · wk 0.29 · n 9 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 56 mg · wk 0.29 · n 9 · Phase 2 · secondary NCT01998958
  • 18.2% vs 3% 56 mg · wk 0.14 · n 11 · Phase 2 · secondary NCT01998958
  • 33.3% vs 3% 56 mg · wk 0.14 · n 9 · Phase 2 · secondary NCT01998958
  • 0% vs 16.7% 56 mg · wk 0.14 · n 9 · Phase 2 · secondary NCT01998958
  • 9.1% vs 3% 28 mg · wk 1.14 · n 11 · Phase 2 · secondary NCT01998958
  • 12.5% vs 0% 28 mg · wk 1.14 · n 8 · Phase 2 · secondary NCT01998958
  • 36.4% vs 0% 28 mg · wk 0.29 · n 11 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 28 mg · wk 0.29 · n 8 · Phase 2 · secondary NCT01998958
  • 27.3% vs 3% 28 mg · wk 0.14 · n 11 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 56 mg · wk 1.14 · n 3 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 56 mg · wk 0.29 · n 3 · Phase 2 · secondary NCT01998958
  • 12.5% vs 16.7% 28 mg · wk 0.14 · n 8 · Phase 2 · secondary NCT01998958
  • 18.2% vs 3% 14 mg · wk 1.14 · n 11 · Phase 2 · secondary NCT01998958
  • 0% vs 0% 14 mg · wk 1.14 · n 5 · Phase 2 · secondary NCT01998958
  • 27.3% vs 0% 14 mg · wk 0.29 · n 11 · Phase 2 · secondary NCT01998958
  • 80% vs 0% 14 mg · wk 0.29 · n 5 · Phase 2 · secondary NCT01998958
  • 36.4% vs 3% 14 mg · wk 0.14 · n 11 · Phase 2 · secondary NCT01998958
  • 0% vs 16.7% 56 mg · wk 0.14 · n 3 · Phase 2 · secondary NCT01998958
  • 60% vs 16.7% 14 mg · wk 0.14 · n 5 · Phase 2 · secondary NCT01998958
SP-101
—Not reported

Relapse (% of patients)

Esketamine
—Trial running · NCT07153406
SP-101
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SP-101: no structured comparison results are available for Major Depressive Disorder.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Esketamine: 4 of 4 rows · SP-101: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEsketamine
Dropout rate
—84 mga
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
show 75 more results
—84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
16.4%84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
5.1%56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—DB Phase: Intranasal Esk + Oral AD
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—FU Phase: Intranasal Esk + Oral AD
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
15.5%Intranasal Esketamine (Esk) Plus O
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—Esketamine Nasal Spray (IND Phase)
NCT02782104 · Phase 3 · monotherapy
—Esketamine Nasal Spray (OP/MA Phas
NCT02782104 · Phase 3 · monotherapy
—84 mg
NCT04599855 · Phase 4
—OL Treatment: Esketamine 84 mg to
NCT04599855 · Phase 4
—56 mg
NCT04599855 · Phase 4
—OL Treatment: Esketamine 56 mg to
NCT04599855 · Phase 4
—OL Treatment: Placebo to Esketamin
NCT04599855 · Phase 4
—Esketamine + Oral AD
NCT04829318 · Phase 4 · registry result, not featured evidence · combination
19.1%Esketamine Nasal Spray + Oral Anti
NCT04829318 · Phase 4 · registry result, not featured evidence · combination
18.5%
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
—Double-blind: Intranasal Esketamin
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
—Follow-up: Intranasal Esketamine+
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
14.3%Intranasal Esketamine + Oral Antid
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
29.6%84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence
26.3%84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
—FU: Intranasal Esketamine + Oral A
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
—IND: Intranasal Esketamine + Oral
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
37.5%Intranasal Esketamine + Oral AD
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
—MA: Intranasal Esketamine + Oral A
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
—OP: Intranasal Esketamine + Oral A
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
—FU: Intranasal Esketamine + Oral A
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
—IND: Intranasal Esketamine + Oral
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
25.5%Intranasal Esketamine + Oral Antid
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
—OP/MA: Intranasal Esketamine + Ora
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
—DB Phase: Intranasal Esketamine +
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
—Follow-up Phase: Intranasal Esketa
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
13.9%Intranasal Esketamine Plus Oral An
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
—84 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
8.3%84 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—84 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—56 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
6.5%56 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—56 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—28 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
0%28 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—28 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
4.9%84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
—84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
17.5%56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
—56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
4.9%28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
—28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—flexible dose
NCT02918318 · Phase 2 · registry result, not featured evidence
—flexible dose
NCT02918318 · Phase 2 · registry result, not featured evidence
—flexible dose
NCT02918318 · Phase 2 · registry result, not featured evidence
—84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
25%84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
—84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
0%84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
27.3%28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0%14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—Esketamine/Esketamine/Open Label E
NCT01998958 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—84 mga
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
show 75 more results
—84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
6%84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
0.9%56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—DB Phase: Intranasal Esk + Oral AD
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—FU Phase: Intranasal Esk + Oral AD
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
7.8%Intranasal Esketamine (Esk) Plus O
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—Esketamine Nasal Spray (IND Phase)
NCT02782104 · Phase 3 · monotherapy
—Esketamine Nasal Spray (OP/MA Phas
NCT02782104 · Phase 3 · monotherapy
—84 mg
NCT04599855 · Phase 4
—OL Treatment: Esketamine 84 mg to
NCT04599855 · Phase 4
—56 mg
NCT04599855 · Phase 4
—OL Treatment: Esketamine 56 mg to
NCT04599855 · Phase 4
—OL Treatment: Placebo to Esketamin
NCT04599855 · Phase 4
—Esketamine + Oral AD
NCT04829318 · Phase 4 · registry result, not featured evidence · combination
3.3%Esketamine Nasal Spray + Oral Anti
NCT04829318 · Phase 4 · registry result, not featured evidence · combination
1.2%
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
—Double-blind: Intranasal Esketamin
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
—Follow-up: Intranasal Esketamine+
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
5.6%Intranasal Esketamine + Oral Antid
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
0%84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence
2.6%84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
—FU: Intranasal Esketamine + Oral A
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
—IND: Intranasal Esketamine + Oral
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
5%Intranasal Esketamine + Oral AD
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
—MA: Intranasal Esketamine + Oral A
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
—OP: Intranasal Esketamine + Oral A
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
—FU: Intranasal Esketamine + Oral A
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
—IND: Intranasal Esketamine + Oral
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
6.7%Intranasal Esketamine + Oral Antid
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
—OP/MA: Intranasal Esketamine + Ora
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
—DB Phase: Intranasal Esketamine +
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
—Follow-up Phase: Intranasal Esketa
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
5.6%Intranasal Esketamine Plus Oral An
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
—84 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
0%84 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—84 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—56 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
0%56 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—56 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—28 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
0%28 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—28 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
4.9%84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
—84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
10%56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
—56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
2.4%28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
—28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—flexible dose
NCT02918318 · Phase 2 · registry result, not featured evidence
—flexible dose
NCT02918318 · Phase 2 · registry result, not featured evidence
—flexible dose
NCT02918318 · Phase 2 · registry result, not featured evidence
—84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
13.9%84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
—84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
0%84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
9.1%28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0%14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
—Esketamine/Esketamine/Open Label E
NCT01998958 · Phase 2 · registry result, not featured evidence
Serious AEs
0%84 mga
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
show 75 more results
3.8%84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
1.7%56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
4.3%56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
0.9%DB Phase: Intranasal Esk + Oral AD
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
2.9%FU Phase: Intranasal Esk + Oral AD
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
—Intranasal Esketamine (Esk) Plus O
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
1.1%Esketamine Nasal Spray (IND Phase)
NCT02782104 · Phase 3 · monotherapy
19.1%Esketamine Nasal Spray (OP/MA Phas
NCT02782104 · Phase 3 · monotherapy
1.7%84 mg
NCT04599855 · Phase 4
0%OL Treatment: Esketamine 84 mg to
NCT04599855 · Phase 4
1%56 mg
NCT04599855 · Phase 4
3%OL Treatment: Esketamine 56 mg to
NCT04599855 · Phase 4
2.5%OL Treatment: Placebo to Esketamin
NCT04599855 · Phase 4
6%Esketamine + Oral AD
NCT04829318 · Phase 4 · registry result, not featured evidence · combination
—Esketamine Nasal Spray + Oral Anti
NCT04829318 · Phase 4 · registry result, not featured evidence · combination
5.7%
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
2.4%Double-blind: Intranasal Esketamin
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
1.9%Follow-up: Intranasal Esketamine+
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
—Intranasal Esketamine + Oral Antid
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
4.4%84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence
3.5%84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
0.6%FU: Intranasal Esketamine + Oral A
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
3%IND: Intranasal Esketamine + Oral
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
—Intranasal Esketamine + Oral AD
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
2.6%MA: Intranasal Esketamine + Oral A
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
2.4%OP: Intranasal Esketamine + Oral A
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
2.2%FU: Intranasal Esketamine + Oral A
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
2.2%IND: Intranasal Esketamine + Oral
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
—Intranasal Esketamine + Oral Antid
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
6.3%OP/MA: Intranasal Esketamine + Ora
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
4.2%DB Phase: Intranasal Esketamine +
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
0%Follow-up Phase: Intranasal Esketa
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
—Intranasal Esketamine Plus Oral An
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
4.3%84 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—84 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
33.3%84 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
22.6%56 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—56 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
27.6%56 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
13.8%28 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
—28 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
34.5%28 mg
NCT03185819 · Phase 2 · registry result, not featured evidence
4.3%84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
2.5%84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
0%84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
0%56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
0%56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
0%56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
0%28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
2.4%28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
0%28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence
—flexible dose
NCT02918318 · Phase 2 · registry result, not featured evidence
4.2%flexible dose
NCT02918318 · Phase 2 · registry result, not featured evidence
2.1%flexible dose
NCT02918318 · Phase 2 · registry result, not featured evidence
11.4%84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
—84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
3.7%84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
0%84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0%84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
2.4%84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0%56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0%56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
2.6%56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0%28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0%28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
8.3%28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0%14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0%14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0%14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
2.2%Esketamine/Esketamine/Open Label E
NCT01998958 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
84 mga
nausea 31.9% (placebo 10.6%)
dissociation 27.6% (placebo 3.5%)
dizziness 22.4% (placebo 8.8%)
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
show 59 more results
84 mg
headache 3.8% (placebo 16.8%)
diarrhoea 1.9% (placebo 2.7%)
dizziness 1.9% (placebo 8.8%)
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
56 mg
dizziness 27.8% (placebo 8.8%)
nausea 27% (placebo 10.6%)
dissociation 26.1% (placebo 3.5%)
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
56 mg
headache 8.5% (placebo 16.8%)
nausea 4.3% (placebo 10.6%)
anxiety 2.1% (placebo 6.2%)
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
dissociation 26.1% (placebo 3.7%)
nausea 26.1% (placebo 6.4%)
vertigo 26.1% (placebo 2.8%)
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
upper respiratory tract infection 8.8% (placebo 0.9%)
decreased appetite 5.9% (placebo 2.8%)
headache 5.9% (placebo 17.4%)
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
dissociation 21.8%
dizziness 20.7%
nausea 17.9%
NCT02782104 · Phase 3 · monotherapy
headache 36.1%
dizziness 32.9%
nausea 32.1%
NCT02782104 · Phase 3 · monotherapy
84 mg
dissociation 26.4% (placebo 2.8%)
nausea 26.4% (placebo 8.4%)
dizziness 22.3% (placebo 7.2%)
NCT04599855 · Phase 4
dissociation 14.3% (placebo 2.8%)
nausea 14.3% (placebo 8.4%)
headache 10.5% (placebo 8.8%)
NCT04599855 · Phase 4
56 mg
nausea 22.9% (placebo 8.4%)
dissociation 21.9% (placebo 2.8%)
dizziness 21% (placebo 7.2%)
NCT04599855 · Phase 4
nausea 18.2% (placebo 8.4%)
headache 13.1% (placebo 8.8%)
dissociation 12.1% (placebo 2.8%)
NCT04599855 · Phase 4
nausea 29.1% (placebo 8.4%)
dizziness 19% (placebo 7.2%)
dissociation 17.7% (placebo 2.8%)
NCT04599855 · Phase 4
headache 44.3%
dizziness 27.3%
nasopharyngitis 20.2%
NCT04829318 · Phase 4 · registry result, not featured evidence · combination
dizziness 46.7%
nausea 29.3%
dissociation 28.1%
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
dizziness 77% (placebo 19.8%)
dissociation 59.5% (placebo 6.3%)
nausea 42.1% (placebo 13.5%)
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
headache 2.8% (placebo 11.1%)
insomnia 2.8% (placebo 8.7%)
anxiety 1.9% (placebo 2.4%)
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
84 mg
dizziness 41.2% (placebo 18.6%)
dissociation 38.6% (placebo 8%)
nausea 33.3% (placebo 14.2%)
NCT03097133 · Phase 3 · registry result, not featured evidence
84 mg
dizziness 35.4% (placebo 8.9%)
dissociation 29.2% (placebo 3.6%)
nausea 20.4% (placebo 13.4%)
NCT03039192 · Phase 3 · registry result, not featured evidence
headache 1.7% (placebo 0%)
anxiety 0.4% (placebo 0%)
nausea 0.4% (placebo 1.6%)
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
vertigo 22.7% (placebo 0%)
dizziness 22.2% (placebo 1.6%)
nausea 21.5% (placebo 1.6%)
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
dysgeusia 27% (placebo 0%)
vertigo 25% (placebo 0%)
dissociation 23% (placebo 0%)
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
vertigo 20% (placebo 0%)
dysgeusia 17.4% (placebo 0%)
dissociation 16% (placebo 0%)
NCT02493868 · Phase 3 · registry result, not featured evidence · combination
urinary tract infection 2%
headache 1.1%
upper respiratory tract infection 0.8%
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
dizziness 29.3%
dissociation 23.4%
nausea 20.2%
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
dizziness 22.4%
headache 18.9%
dissociation 18.7%
NCT02497287 · Phase 3 · registry result, not featured evidence · combination
dizziness 20.8%
nausea 18.1%
blood pressure increased 12.5%
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
constipation 8.3%
anxiety 0%
blood pressure increased 0%
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
84 mg
dizziness 69.6% (placebo 42.9%)
nausea 56.5% (placebo 17.5%)
dissociation 47.8% (placebo 17.5%)
NCT03185819 · Phase 2 · registry result, not featured evidence
84 mg
intentional self-injury 33.3% (placebo 19%)
depression 19% (placebo 3.2%)
anxiety 14.3% (placebo 15.9%)
NCT03185819 · Phase 2 · registry result, not featured evidence
56 mg
dizziness 51.6% (placebo 42.9%)
nausea 48.4% (placebo 17.5%)
headache 41.9% (placebo 28.6%)
NCT03185819 · Phase 2 · registry result, not featured evidence
56 mg
headache 24.1% (placebo 28.6%)
anxiety 13.8% (placebo 15.9%)
diarrhoea 10.3% (placebo 4.8%)
NCT03185819 · Phase 2 · registry result, not featured evidence
28 mg
dizziness 55.2% (placebo 42.9%)
dissociation 41.4% (placebo 17.5%)
dysgeusia 34.5% (placebo 23.8%)
NCT03185819 · Phase 2 · registry result, not featured evidence
28 mg
headache 34.5% (placebo 28.6%)
intentional self-injury 24.1% (placebo 19%)
insomnia 13.8% (placebo 12.7%)
NCT03185819 · Phase 2 · registry result, not featured evidence
84 mg
headache 4.3% (placebo 0%)
muscular weakness 4.3% (placebo 1.9%)
nasopharyngitis 4.3% (placebo 5.7%)
NCT02918318 · Phase 2 · registry result, not featured evidence
84 mg
dissociation 55% (placebo 0%)
blood pressure increased 47.5% (placebo 0%)
dizziness 37.5% (placebo 1.9%)
NCT02918318 · Phase 2 · registry result, not featured evidence
84 mg
nasopharyngitis 11.8% (placebo 5.7%)
anxiety 5.9% (placebo 0%)
asthenia 5.9% (placebo 0%)
NCT02918318 · Phase 2 · registry result, not featured evidence
56 mg
dizziness 3.4% (placebo 1.9%)
nasopharyngitis 3.4% (placebo 5.7%)
vomiting 3.4% (placebo 0%)
NCT02918318 · Phase 2 · registry result, not featured evidence
56 mg
blood pressure increased 46.3% (placebo 0%)
dizziness 43.9% (placebo 1.9%)
somnolence 31.7% (placebo 1.9%)
NCT02918318 · Phase 2 · registry result, not featured evidence
56 mg
nasopharyngitis 18.2% (placebo 5.7%)
agitation 9.1% (placebo 0%)
albuminuria 9.1% (placebo 0%)
NCT02918318 · Phase 2 · registry result, not featured evidence
28 mg
nasopharyngitis 7.4% (placebo 5.7%)
anxiety 3.7% (placebo 0%)
dizziness 3.7% (placebo 1.9%)
NCT02918318 · Phase 2 · registry result, not featured evidence
28 mg
dissociation 34.1% (placebo 0%)
blood pressure increased 29.3% (placebo 0%)
dizziness 26.8% (placebo 1.9%)
NCT02918318 · Phase 2 · registry result, not featured evidence
28 mg
nasopharyngitis 15.4% (placebo 5.7%)
conjunctivitis allergic 7.7% (placebo 0%)
dizziness 7.7% (placebo 1.9%)
NCT02918318 · Phase 2 · registry result, not featured evidence
flexible dose
nasopharyngitis 4.2% (placebo 5.7%)
dizziness postural 2.1% (placebo 0%)
hypoaesthesia 2.1% (placebo 0%)
NCT02918318 · Phase 2 · registry result, not featured evidence
flexible dose
dissociation 64.6% (placebo 0%)
blood pressure increased 50% (placebo 0%)
dizziness 43.8% (placebo 1.9%)
NCT02918318 · Phase 2 · registry result, not featured evidence
84 mg
nausea 37.1% (placebo 3.2%)
dizziness 34.3% (placebo 12.9%)
dissociation 31.4% (placebo 12.9%)
NCT02133001 · Phase 2 · registry result, not featured evidence
84 mg
insomnia 11.1% (placebo 6.5%)
dry mouth 7.4% (placebo 0%)
headache 7.4% (placebo 25.8%)
NCT02133001 · Phase 2 · registry result, not featured evidence
84 mg
dizziness 41.7% (placebo 1.9%)
dissociation 25% (placebo 1.9%)
dissociative disorder 25% (placebo 0%)
NCT01998958 · Phase 2 · registry result, not featured evidence
84 mg
dizziness 29.4% (placebo 1.9%)
dysgeusia 23.5% (placebo 16.7%)
dissociative disorder 17.6% (placebo 0%)
NCT01998958 · Phase 2 · registry result, not featured evidence
84 mg
headache 9.5% (placebo 7.4%)
decreased appetite 2.4% (placebo 0%)
nasopharyngitis 2.4% (placebo 1.9%)
NCT01998958 · Phase 2 · registry result, not featured evidence
56 mg
dizziness 35% (placebo 1.9%)
dissociation 30% (placebo 1.9%)
nausea 25% (placebo 9.3%)
NCT01998958 · Phase 2 · registry result, not featured evidence
56 mg
dizziness 34.4% (placebo 1.9%)
dissociation 25% (placebo 1.9%)
somnolence 15.6% (placebo 5.6%)
NCT01998958 · Phase 2 · registry result, not featured evidence
56 mg
nasopharyngitis 12.8% (placebo 1.9%)
asthenia 2.6% (placebo 0%)
decreased appetite 2.6% (placebo 0%)
NCT01998958 · Phase 2 · registry result, not featured evidence
28 mg
dizziness 36.4% (placebo 1.9%)
headache 36.4% (placebo 7.4%)
dysgeusia 18.2% (placebo 16.7%)
NCT01998958 · Phase 2 · registry result, not featured evidence
28 mg
dizziness 12.5% (placebo 1.9%)
headache 12.5% (placebo 7.4%)
blood pressure diastolic increased 6.3% (placebo 0%)
NCT01998958 · Phase 2 · registry result, not featured evidence
28 mg
arthropod bite 8.3% (placebo 0%)
bladder pain 8.3% (placebo 0%)
blood pressure increased 8.3% (placebo 1.9%)
NCT01998958 · Phase 2 · registry result, not featured evidence
14 mg
feeling abnormal 18.2% (placebo 1.9%)
headache 18.2% (placebo 7.4%)
somnolence 18.2% (placebo 5.6%)
NCT01998958 · Phase 2 · registry result, not featured evidence
14 mg
feeling abnormal 25% (placebo 1.9%)
hypoaesthesia 18.8% (placebo 0%)
dizziness 12.5% (placebo 1.9%)
NCT01998958 · Phase 2 · registry result, not featured evidence
14 mg
headache 25% (placebo 7.4%)
insomnia 25% (placebo 1.9%)
abdominal pain 0% (placebo 0%)
NCT01998958 · Phase 2 · registry result, not featured evidence
dizziness 30.4% (placebo 1.9%)
dysgeusia 19.6% (placebo 16.7%)
dissociation 17.4% (placebo 1.9%)
NCT01998958 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 67 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Esketamine

MADRS -13.9 vs -7 placebo score @ 4wk84 mg
absolute change · score
Induction
NCT04599855 · Phase 4
show 64 more results
-13 vs -9.7 placebo score @ 0.14wk84 mg
NCT04599855 · Phase 4
-15.7 vs -12.4 placebo score @ 0.14wk84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence
-16 vs -12.4 placebo score @ 0.29wk84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence
-17.7 vs -15.7 placebo score @ 0.57wk84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence
-20.1 vs -17.4 placebo score @ 1.14wk84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence
-21.3 vs -19.5 placebo score @ 1.57wk84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence
-23.4 vs -20 placebo score @ 2.14wk84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence
-23.1 vs -21.4 placebo score @ 2.57wk84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence
-24.5 vs -22 placebo score @ 3.14wk84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence
-16.4 vs -12.8 placebo score @ 0.14wk84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
-13.5 vs -10.9 placebo score @ 0.14wk84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
-16.4 vs -12.9 placebo score @ 0.29wk84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
-19.1 vs -14.5 placebo score @ 0.57wk84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
-19.7 vs -17.4 placebo score @ 1.14wk84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
-21.8 vs -19 placebo score @ 1.57wk84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
-22.3 vs -20.4 placebo score @ 2.14wk84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
-23.9 vs -21.4 placebo score @ 2.57wk84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
-24 vs -21.6 placebo score @ 3.14wk84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
-29.5 vs -25.8 placebo score @ 3.57wk84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence
-15.1 vs -15.3 placebo score @ 4wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-13.4 vs -9.1 placebo score @ 0.0238wk84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
-19.3 vs -12.8 placebo score @ 0.1429wk84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
-26.4 vs -23 placebo score @ 3.4286wk84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
-15.3 vs -4.9 placebo score @ 1wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-11.4 vs -4.5 placebo score @ 1wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-18.8 vs -14.8 placebo score @ 4wk84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-17.4 vs -14.3 placebo score @ 4wk84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-19 vs -14.8 placebo score @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-18.3 vs -14.3 placebo score @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-12.7 vs -7 placebo score @ 4wk56 mg
NCT04599855 · Phase 4
-13.9 vs -9.7 placebo score @ 0.14wk56 mg
NCT04599855 · Phase 4
-14.5 vs -15.3 placebo score @ 4wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-12.4 vs -4.9 placebo score @ 1wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-10.3 vs -4.9 placebo score @ 1wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-8.9 vs -4.5 placebo score @ 1wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-1.2 vs -4.5 placebo score @ 1wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-15.2 vs -15.3 placebo score @ 4wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-9.8 vs -4.9 placebo score @ 1wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-7.6 vs -4.5 placebo score @ 1wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-4.8 vs -4.9 placebo score @ 1wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-6.6 vs -4.5 placebo score @ 1wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-21.4 vs -17 placebo score @ 4wk
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-19.6 vs -16.3 placebo score @ 4wk
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-5.3 vs -3.7 Quetiapine Extended Release (XR) + Oral AD score @ 1wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-9 vs -6.1 Quetiapine Extended Release (XR) + Oral AD score @ 2wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-12.8 vs -9.8 Quetiapine Extended Release (XR) + Oral AD score @ 4wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-14.9 vs -12.2 Quetiapine Extended Release (XR) + Oral AD score @ 6wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-16.4 vs -14.3 Quetiapine Extended Release (XR) + Oral AD score @ 8wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-18.2 vs -16.2 Quetiapine Extended Release (XR) + Oral AD score @ 10wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-18.4 vs -16.7 Quetiapine Extended Release (XR) + Oral AD score @ 12wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-19 vs -17.1 Quetiapine Extended Release (XR) + Oral AD score @ 14wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-19.6 vs -17.8 Quetiapine Extended Release (XR) + Oral AD score @ 16wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-9 vs -5.8 Quetiapine Extended Release (XR) + Oral AD score @ 2wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-12.6 vs -8.9 Quetiapine Extended Release (XR) + Oral AD score @ 4wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-14.5 vs -10.7 Quetiapine Extended Release (XR) + Oral AD score @ 6wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-15.7 vs -12 Quetiapine Extended Release (XR) + Oral AD score @ 8wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-16.9 vs -12.8 Quetiapine Extended Release (XR) + Oral AD score @ 10wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-17.1 vs -13.1 Quetiapine Extended Release (XR) + Oral AD score @ 12wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-17.6 vs -13.2 Quetiapine Extended Release (XR) + Oral AD score @ 14wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-18.1 vs -13.7 Quetiapine Extended Release (XR) + Oral AD score @ 16wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-10.1 vs -8.1 placebo score @ 4wk
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
-8 vs -4.4 placebo score @ 0.14wk
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
-10 vs -6.3 oral AD score @ 4wk
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
-9.3 vs -5.6 oral AD score @ 4wk
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
SDS Total -9.5 vs -7 placebo score @ 4wk84 mg
absolute change · score
Induction
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
show 39 more results
-13.1 vs -11.2 placebo score @ 2wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-13.6 vs -9.8 placebo score @ 4wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-14.6 vs -12 placebo score @ 6wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-15.3 vs -11.4 placebo score @ 8wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-18.3 vs -14.8 placebo score @ 12wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-12.5 vs -15.8 placebo score @ 16wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-28 vs -14 placebo score @ 20wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-28 vs -14.8 placebo score @ 24wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-11.1 vs -8.4 placebo score @ 4wk84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-10.2 vs -8.1 placebo score @ 4wk84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-11 vs -8.4 placebo score @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-10.7 vs -8.1 placebo score @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-7.9 vs -7 placebo score @ 4wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-8.1 vs -11.2 placebo score @ 2wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-8.3 vs -9.8 placebo score @ 4wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-11 vs -12 placebo score @ 6wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-13.3 vs -11.4 placebo score @ 8wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-13 vs -14.8 placebo score @ 12wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-17.5 vs -15.8 placebo score @ 16wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-18 vs -14 placebo score @ 20wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-16 vs -14.8 placebo score @ 24wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-8.6 vs -7 placebo score @ 4wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-14.6 vs -11.2 placebo score @ 2wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-12.9 vs -9.8 placebo score @ 4wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-17.7 vs -12 placebo score @ 6wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-12 vs -11.4 placebo score @ 8wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-20.5 vs -14.8 placebo score @ 12wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-21.5 vs -15.8 placebo score @ 16wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-22 vs -14 placebo score @ 20wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-21.5 vs -14.8 placebo score @ 24wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-5.9 vs -4.1 Quetiapine Extended Release (XR) + Oral AD score @ 4wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-8.6 vs -6.8 Quetiapine Extended Release (XR) + Oral AD score @ 8wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-9.7 vs -8.6 Quetiapine Extended Release (XR) + Oral AD score @ 12wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-10.6 vs -9 Quetiapine Extended Release (XR) + Oral AD score @ 16wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-5.9 vs -4.1 Quetiapine Extended Release (XR) + Oral AD score @ 4wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-8.2 vs -5.8 Quetiapine Extended Release (XR) + Oral AD score @ 8wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-9 vs -6.8 Quetiapine Extended Release (XR) + Oral AD score @ 12wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-9.8 vs -7 Quetiapine Extended Release (XR) + Oral AD score @ 16wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-6.3 vs -5.3 placebo score @ 4wk
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
PHQ-9 Total -11.7 vs -9.1 placebo score @ 4wk84 mg
absolute change · score
Induction
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
show 3 more results
-10.9 vs -8.9 placebo score @ 4wk84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-11 vs -9.1 placebo score @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-10.9 vs -8.9 placebo score @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
MADRS 10% (n=41) vs 9% (n=80) placebo @ 0.29wk84 mg
responder rate · % of participants
Induction
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
show 67 more results
9.8% (n=41) vs 3.8% (n=80) placebo @ 1.14wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
15% (n=41) vs 18.2% (n=80) placebo @ 2.14wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
20.5% (n=41) vs 29.7% (n=80) placebo @ 3.14wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
43.6% (n=41) vs 37.5% (n=80) placebo @ 4wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
25.7% (n=35) vs 12.9% (n=31) placebo @ 0.14wk84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
54.3% (n=35) vs 29% (n=31) placebo @ 0.29wk84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
66.7% (n=27) vs 63.6% (n=22) placebo @ 11.4286wk84 mg
NCT02133001 · Phase 2 · registry result, not featured evidence
30% (n=10) vs 0% (n=10) placebo @ 2wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
25% (n=12) vs 0% (n=10) placebo @ 2wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
58.3% (n=12) vs 18.2% (n=33) placebo @ 0.14wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
41.7% (n=12) vs 3% (n=33) placebo @ 0.29wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
41.7% (n=12) vs 6.1% (n=33) placebo @ 1.14wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
40% (n=5) vs 16.7% (n=6) placebo @ 0.14wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
40% (n=5) vs 0% (n=6) placebo @ 0.29wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
20% (n=5) vs 0% (n=6) placebo @ 1.14wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
53.1% (n=98) vs 38.9% (n=108) placebo @ 4wk84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
47.8% (n=113) vs 37.2% (n=113) placebo @ 4wk84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
54.1% (n=111) vs 38.9% (n=108) placebo @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
53% (n=115) vs 37.2% (n=113) placebo @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
13.2% (n=40) vs 9% (n=80) placebo @ 0.29wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
2.6% (n=40) vs 3.8% (n=80) placebo @ 1.14wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
8.3% (n=40) vs 18.2% (n=80) placebo @ 2.14wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
13.9% (n=40) vs 29.7% (n=80) placebo @ 3.14wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
35.3% (n=40) vs 37.5% (n=80) placebo @ 4wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
9.1% (n=11) vs 0% (n=10) placebo @ 2wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
22.2% (n=9) vs 0% (n=10) placebo @ 2wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
9.1% (n=11) vs 0% (n=10) placebo @ 2wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
22.2% (n=9) vs 0% (n=10) placebo @ 2wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
36.4% (n=11) vs 18.2% (n=33) placebo @ 0.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
44.4% (n=9) vs 18.2% (n=33) placebo @ 0.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
27.3% (n=11) vs 3% (n=33) placebo @ 0.29wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
44.4% (n=9) vs 3% (n=33) placebo @ 0.29wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
18.2% (n=11) vs 6.1% (n=33) placebo @ 1.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
22.2% (n=9) vs 6.1% (n=33) placebo @ 1.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
22.2% (n=9) vs 16.7% (n=6) placebo @ 0.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=3) vs 16.7% (n=6) placebo @ 0.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
11.1% (n=9) vs 0% (n=6) placebo @ 0.29wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=3) vs 0% (n=6) placebo @ 0.29wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=9) vs 0% (n=6) placebo @ 1.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
33.3% (n=3) vs 0% (n=6) placebo @ 1.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
22% (n=41) vs 9% (n=80) placebo @ 0.29wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
2.4% (n=41) vs 3.8% (n=80) placebo @ 1.14wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
17.5% (n=41) vs 18.2% (n=80) placebo @ 2.14wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
23.1% (n=41) vs 29.7% (n=80) placebo @ 3.14wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
33.3% (n=41) vs 37.5% (n=80) placebo @ 4wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
12.5% (n=8) vs 0% (n=10) placebo @ 2wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
12.5% (n=8) vs 0% (n=10) placebo @ 2wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
54.5% (n=11) vs 18.2% (n=33) placebo @ 0.14wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
36.4% (n=11) vs 3% (n=33) placebo @ 0.29wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
9.1% (n=11) vs 6.1% (n=33) placebo @ 1.14wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
12.5% (n=8) vs 16.7% (n=6) placebo @ 0.14wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=8) vs 0% (n=6) placebo @ 0.29wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
12.5% (n=8) vs 0% (n=6) placebo @ 1.14wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
18.2% (n=11) vs 0% (n=10) placebo @ 2wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
18.2% (n=11) vs 0% (n=10) placebo @ 2wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
36.4% (n=11) vs 18.2% (n=33) placebo @ 0.14wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
36.4% (n=11) vs 3% (n=33) placebo @ 0.29wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
18.2% (n=11) vs 6.1% (n=33) placebo @ 1.14wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
60% (n=5) vs 16.7% (n=6) placebo @ 0.14wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
80% (n=5) vs 0% (n=6) placebo @ 0.29wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=5) vs 0% (n=6) placebo @ 1.14wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
7.9% (n=114) vs 4.6% (n=109) placebo @ 0.29wk
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
10.5% (n=114) vs 6.4% (n=109) placebo @ 1.14wk
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
63.4% (n=112) vs 49.5% (n=109) placebo @ 4wk
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
6.5% (n=124) vs 1.6% (n=126) placebo @ 4wk
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
19.3% (n=109) vs 16% (n=106) placebo @ 4wk
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
23.9% (n=71) vs 12.5% (n=64) oral AD @ 4wk
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
MADRS Remission 21.9% (n=114) vs 10.6% (n=113) placebo @ 0.29wk84 mg
responder rate · % of participants
Induction
NCT03097133 · Phase 3 · registry result, not featured evidence · converted to % from 25 Participants as posted
show 67 more results
22.8% (n=114) vs 17.7% (n=113) placebo @ 0.57wk*84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence · converted to % from 26 Participants as posted
24.6% (n=114) vs 20.4% (n=113) placebo @ 1.14wk*84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence · converted to % from 28 Participants as posted
28.1% (n=114) vs 23% (n=113) placebo @ 1.57wk*84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence · converted to % from 32 Participants as posted
31.6% (n=114) vs 25.7% (n=113) placebo @ 2.14wk*84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence · converted to % from 36 Participants as posted
25.4% (n=114) vs 28.3% (n=113) placebo @ 2.57wk*84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence · converted to % from 29 Participants as posted
36.8% (n=114) vs 32.7% (n=113) placebo @ 3.14wk*84 mg
NCT03097133 · Phase 3 · registry result, not featured evidence · converted to % from 42 Participants as posted
10.7% (n=112) vs 8% (n=112) placebo @ 0.14wk*84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence · converted to % from 12 Participants as posted
18.8% (n=112) vs 8.9% (n=112) placebo @ 0.29wk*84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence · converted to % from 21 Participants as posted
25% (n=112) vs 11.6% (n=112) placebo @ 0.57wk*84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence · converted to % from 28 Participants as posted
26.8% (n=112) vs 20.5% (n=112) placebo @ 1.14wk*84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence · converted to % from 30 Participants as posted
29.5% (n=112) vs 23.2% (n=112) placebo @ 1.57wk*84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence · converted to % from 33 Participants as posted
33.9% (n=112) vs 25.9% (n=112) placebo @ 2.14wk*84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence · converted to % from 38 Participants as posted
37.5% (n=112) vs 26.8% (n=112) placebo @ 2.57wk*84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence · converted to % from 42 Participants as posted
36.6% (n=112) vs 22.3% (n=112) placebo @ 3.14wk*84 mg
NCT03039192 · Phase 3 · registry result, not featured evidence · converted to % from 41 Participants as posted
7.5% (n=41) vs 3.8% (n=80) placebo @ 0.29wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
4.9% (n=41) vs 1.3% (n=80) placebo @ 1.14wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
10% (n=41) vs 3.9% (n=80) placebo @ 2.14wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
7.7% (n=41) vs 14.9% (n=80) placebo @ 3.14wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
23.1% (n=41) vs 20.8% (n=80) placebo @ 4wk84 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
25% (n=12) vs 3% (n=33) placebo @ 0.14wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
25% (n=12) vs 0% (n=33) placebo @ 0.29wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
25% (n=12) vs 3% (n=33) placebo @ 1.14wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
40% (n=5) vs 16.7% (n=6) placebo @ 0.14wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
20% (n=5) vs 0% (n=6) placebo @ 0.29wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
20% (n=5) vs 0% (n=6) placebo @ 1.14wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
38.8% (n=98) vs 30.6% (n=108) placebo @ 4wk84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
35.4% (n=113) vs 29.2% (n=113) placebo @ 4wk84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
36% (n=111) vs 30.6% (n=108) placebo @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
34.8% (n=115) vs 29.2% (n=113) placebo @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
0% (n=40) vs 3.8% (n=80) placebo @ 0.29wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
0% (n=40) vs 1.3% (n=80) placebo @ 1.14wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
2.8% (n=40) vs 3.9% (n=80) placebo @ 2.14wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
5.6% (n=40) vs 14.9% (n=80) placebo @ 3.14wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
11.8% (n=40) vs 20.8% (n=80) placebo @ 4wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
18.2% (n=11) vs 3% (n=33) placebo @ 0.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
33.3% (n=9) vs 3% (n=33) placebo @ 0.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
18.2% (n=11) vs 0% (n=33) placebo @ 0.29wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
33.3% (n=9) vs 0% (n=33) placebo @ 0.29wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
9.1% (n=11) vs 3% (n=33) placebo @ 1.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
22.2% (n=9) vs 3% (n=33) placebo @ 1.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=9) vs 16.7% (n=6) placebo @ 0.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=3) vs 16.7% (n=6) placebo @ 0.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=9) vs 0% (n=6) placebo @ 0.29wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=3) vs 0% (n=6) placebo @ 0.29wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=9) vs 0% (n=6) placebo @ 1.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=3) vs 0% (n=6) placebo @ 1.14wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
9.8% (n=41) vs 3.8% (n=80) placebo @ 0.29wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
2.4% (n=41) vs 1.3% (n=80) placebo @ 1.14wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
7.5% (n=41) vs 3.9% (n=80) placebo @ 2.14wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
10.3% (n=41) vs 14.9% (n=80) placebo @ 3.14wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
23.1% (n=41) vs 20.8% (n=80) placebo @ 4wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
27.3% (n=11) vs 3% (n=33) placebo @ 0.14wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
36.4% (n=11) vs 0% (n=33) placebo @ 0.29wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
9.1% (n=11) vs 3% (n=33) placebo @ 1.14wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
12.5% (n=8) vs 16.7% (n=6) placebo @ 0.14wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=8) vs 0% (n=6) placebo @ 0.29wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
12.5% (n=8) vs 0% (n=6) placebo @ 1.14wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
36.4% (n=11) vs 3% (n=33) placebo @ 0.14wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
27.3% (n=11) vs 0% (n=33) placebo @ 0.29wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
18.2% (n=11) vs 3% (n=33) placebo @ 1.14wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
60% (n=5) vs 16.7% (n=6) placebo @ 0.14wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
80% (n=5) vs 0% (n=6) placebo @ 0.29wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
0% (n=5) vs 0% (n=6) placebo @ 1.14wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
48.2% (n=112) vs 30.3% (n=109) placebo @ 4wk
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
27.1% (n=336) vs 17.6% (n=340) Quetiapine Extended Release (XR) + Oral AD @ 8wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
12.8% (n=109) vs 10.4% (n=106) placebo @ 4wk
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
15.5% (n=71) vs 6.3% (n=64) oral AD @ 4wk
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
CGI-S -1 vs -1 placebo score @ 4wk84 mg
absolute change · score
Induction
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
show 30 more results
4 vs 5 placebo score @ 1wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
4 vs 5 placebo score @ 1wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-2 vs -1 placebo score @ 4wk84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-2 vs -1 placebo score @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-1 vs -1 placebo score @ 4wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
4 vs 5 placebo score @ 1wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
3 vs 5 placebo score @ 1wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
5 vs 5 placebo score @ 1wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
4 vs 5 placebo score @ 1wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-1 vs -1 placebo score @ 4wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
4 vs 5 placebo score @ 1wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
4 vs 5 placebo score @ 1wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
4 vs 5 placebo score @ 1wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
3 vs 5 placebo score @ 1wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-2 vs -2 placebo score @ 4wk
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-0.3 vs -0.2 Quetiapine Extended Release (XR) + Oral AD score @ 1wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-0.7 vs -0.5 Quetiapine Extended Release (XR) + Oral AD score @ 2wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-1 vs -0.7 Quetiapine Extended Release (XR) + Oral AD score @ 3wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-1.3 vs -1 Quetiapine Extended Release (XR) + Oral AD score @ 4wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-1.7 vs -1.4 Quetiapine Extended Release (XR) + Oral AD score @ 8wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-1.9 vs -1.7 Quetiapine Extended Release (XR) + Oral AD score @ 12wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-2.1 vs -1.9 Quetiapine Extended Release (XR) + Oral AD score @ 16wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-0.7 vs -0.5 Quetiapine Extended Release (XR) + Oral AD score @ 2wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-1 vs -0.7 Quetiapine Extended Release (XR) + Oral AD score @ 3wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-1.3 vs -0.9 Quetiapine Extended Release (XR) + Oral AD score @ 4wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-1.6 vs -1.2 Quetiapine Extended Release (XR) + Oral AD score @ 8wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-1.8 vs -1.3 Quetiapine Extended Release (XR) + Oral AD score @ 12wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-1.9 vs -1.4 Quetiapine Extended Release (XR) + Oral AD score @ 16wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-1 vs -1 placebo score @ 4wk
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
-1 vs 0 oral AD score @ 4wk
NCT02422186 · Phase 3 · registry result, not featured evidence · combination
GAD-7 -8.1 vs -7.7 placebo score @ 4wk84 mg
absolute change · score
Induction
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
show 16 more results
-5.1 vs -1.7 placebo score @ 1wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-0.9 vs 0.4 placebo score @ 1wk84 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-7.7 vs -6 placebo score @ 4wk84 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-7.4 vs -6 placebo score @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-7.8 vs -7.7 placebo score @ 4wk56 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-3.1 vs -1.7 placebo score @ 1wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-3.2 vs -1.7 placebo score @ 1wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
1 vs 0.4 placebo score @ 1wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-0.7 vs 0.4 placebo score @ 1wk56 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-8.2 vs -7.7 placebo score @ 4wk28 mg
NCT02918318 · Phase 2 · registry result, not featured evidence · add on
-1.5 vs -1.7 placebo score @ 1wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-1.6 vs 0.4 placebo score @ 1wk28 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-1.9 vs -1.7 placebo score @ 1wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-6.6 vs 0.4 placebo score @ 1wk14 mg
NCT01998958 · Phase 2 · registry result, not featured evidence
-7.9 vs -6.8 placebo score @ 4wk
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-4.3 vs -2.9 placebo score @ 4wk
NCT03434041 · Phase 3 · registry result, not featured evidence · combination
EQ-5D Index 0.243 vs 0.181 placebo score @ 4wk84 mg
absolute change · score
Induction
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
show 1 more result
0.224 vs 0.181 placebo score @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
EQ-5D VAS 19.1 vs 14.9 placebo score @ 4wk84 mg
absolute change · score
Induction
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
show 1 more result
20.9 vs 14.9 placebo score @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
EQ-5D Sum -19.4 vs -14.6 placebo score @ 4wk84 mg
absolute change · score
Induction
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
show 1 more result
-19 vs -14.6 placebo score @ 4wk56 mg
NCT02417064 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
SDS -13.6 vs -9.4 placebo score @ 4wk
absolute change · score
Induction
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
show 1 more result
-12.5 vs -9.3 placebo score @ 4wk
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
PHQ-9 -13 vs -10.2 placebo score @ 4wk
absolute change · score
Induction
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
show 17 more results
-12.2 vs -10.1 placebo score @ 4wk
NCT02418585 · Phase 3 · combination · Major Depressive Disorder, Treatment-Resistant Depression · phase 3
-4.9 vs -3.1 Quetiapine Extended Release (XR) + Oral AD score @ 2wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-6.7 vs -5 Quetiapine Extended Release (XR) + Oral AD score @ 4wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-8.1 vs -6.1 Quetiapine Extended Release (XR) + Oral AD score @ 6wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-8.9 vs -7.4 Quetiapine Extended Release (XR) + Oral AD score @ 8wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-9.6 vs -8.4 Quetiapine Extended Release (XR) + Oral AD score @ 10wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-9.8 vs -8.7 Quetiapine Extended Release (XR) + Oral AD score @ 12wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-10.2 vs -8.5 Quetiapine Extended Release (XR) + Oral AD score @ 14wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-10.5 vs -9.2 Quetiapine Extended Release (XR) + Oral AD score @ 16wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-4.9 vs -3.1 Quetiapine Extended Release (XR) + Oral AD score @ 2wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-6.6 vs -4.7 Quetiapine Extended Release (XR) + Oral AD score @ 4wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-7.8 vs -5.6 Quetiapine Extended Release (XR) + Oral AD score @ 6wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-8.5 vs -6.3 Quetiapine Extended Release (XR) + Oral AD score @ 8wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-9 vs -7 Quetiapine Extended Release (XR) + Oral AD score @ 10wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-9.1 vs -7.1 Quetiapine Extended Release (XR) + Oral AD score @ 12wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-9.3 vs -6.9 Quetiapine Extended Release (XR) + Oral AD score @ 14wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination
-9.6 vs -7.4 Quetiapine Extended Release (XR) + Oral AD score @ 16wk
NCT04338321 · Phase 3 · registry result, not featured evidence · combination

+ 159 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Esketamine's landscape · SP-101's landscape